期刊文献+

Optical coherence tomography angiography in diabetic retinopathy: a review of current applications 被引量:7

原文传递
导出
摘要 Background:Diabetic retinopathy(DR)is a leading cause of vision loss in adults.Currently,the standard imaging technique to monitor and prognosticate DR and diabetic maculopathy is dye-based angiography.With the introduction of optical coherence tomography angiography(OCTA),it may serve as a potential rapid,non-invasive imaging modality as an adjunct.Main text:Recent studies on the role of OCTA in DR include the use of vascular parameters e.g.,vessel density,intercapillary spacing,vessel diameter index,length of vessels based on skeletonised OCTA,the total length of vessels,vascular architecture and area of the foveal avascular zone.These quantitative measures may be able to detect changes with the severity and progress of DR for clinical research.OCTA may also serve as a non-invasive imaging method to detect diabetic macula ischemia,which may help predict visual prognosis.However,there are many limitations of OCTA in DR,such as difficulty in segmentation between superficial and deep capillary plexus;and its use in diabetic macula edema where the presence of cystic spaces may affect image results.Future applications of OCTA in the anterior segment include detection of anterior segment ischemia and iris neovascularisation associated with proliferative DR and risk of neovascular glaucoma.Conclusion:OCTA may potentially serve as a useful non-invasive imaging tool in the diagnosis and monitoring of diabetic retinopathy and maculopathy in the future.Future studies may demonstrate how quantitative OCTA measures may have a role in detecting early retinal changes in patients with diabetes.
出处 《Eye and Vision》 SCIE CSCD 2019年第1期312-321,共10页 眼视光学杂志(英文)
  • 相关文献

参考文献2

二级参考文献69

  • 1Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalenceof diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 4-14[PMID: 19896746 DOI: 10.1016/j.diabres.2009.10.007].
  • 2World Health Organization. Diabetes Action Now: An Initiativeof the World Health Organization and the International DiabetesFederation. Switzerland: World Health Organization, 2004.
  • 3Stefánsson E, Bek T, Porta M, Larsen N, Kristinsson JK, Agardh E.Screening and prevention of diabetic blindness. Acta OphthalmolScand 2000; 78: 374-385 [PMID: 10990036 DOI: 10.1034/j.1600-0420.2000.078004374.x].
  • 4Prokofyeva E, Zrenner E. Epidemiology of major eye diseasesleading to blindness in Europe: a literature review. Ophthalmic Res2012; 47: 171-188 [PMID: 22123077 DOI: 10.1159/000329603].
  • 5Hammes HP. Optimal treatment of diabetic retinopathy. Ther AdvEndocrinol Metab 2013; 4: 61-71 [PMID: 23626903 DOI: 10.1177/2042018813477886].
  • 6Deutsche DG. Nationale VersorgungsLeitlinie Typ-2-DiabetesPr-vention und Therapie von Netzhautkomplikationen. Berlin:Bundes-rztekammer (B-K), 2010: 1-42.
  • 7Giani G, Janka HU, Hauner H, Standl E, Schiel R, Neu, A.Epidemiologie und Verlauf des Diabetes mellitus in Deutschland.Evidenzbasierte Leitlinie DDG-Aktualisierung 2004; 5: 1-12.
  • 8Nentwich MM, Ulbig M. Diabetische Retinopathie. DerDiabetologe 2010; 6: 491-502 [DOI: 10.1007/s11428-010-0605-8].
  • 9Kramer CK, Retnakaran R. Concordance of retinopathy andnephropathy over time in Type 1 diabetes: an analysis of data fromthe Diabetes Control and Complications Trial. Diabet Med 2013;30: 1333-1341 [PMID: 23909911 DOI: 10.1111/dme.12296].
  • 10Karlberg C, Falk C, Green A, Sj-lie AK, Grauslund J. Proliferativeretinopathy predicts nephropathy: a 25-year follow-upstudy of type 1 diabetic patients. Acta Diabetol 2012; 49: 263-268[PMID: 21688016 DOI: 10.1007/s00592-011-0304-y].

共引文献53

同被引文献20

引证文献7

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部